| Field | Specification |
|---|---|
| Target | |
| Alternative names | MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1 |
| Gene ID | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human MEK1 around the phosphorylation site of Ser298. AA range:264-313 |
| Conjugate | |
| Concentration | |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
The protein encoded by this gene is a member of the dual specificity protein kinase family, which acts as a mitogen-activated protein (MAP) kinase kinase. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals. This protein kinase lies upstream of MAP kinases and stimulates the enzymatic activity of MAP kinases upon wide variety of extra- and intracellular signals. As an essential component of MAP kinase signal transduction pathway, this kinase is involved in many cellular processes such as proliferation, differentiation, transcription regulation and development. [provided by RefSeq, Jul 2008],
Product Overview
This polyclonal antibody, raised in Rabbit, recognizes MEK-1 (phospho Ser298). It is validated for Western Blot, Immunohistochemistry, Immunofluorescence, ELISA.
Validated Applications
| Applications | Western Blot, Immunohistochemistry, Immunofluorescence, ELISA |
|---|---|
| Western Blot | 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/10000. Not yet tested in other applications. |
Optimal dilutions should be determined by the end user for each application and sample type.
Immunogen
The antiserum was produced against synthesized peptide derived from human MEK1 around the phosphorylation site of Ser298. AA range:264-313
Specifications
| Host | Rabbit |
|---|---|
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse, Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human MEK1 around the phosphorylation site of Ser298. AA range:264-313 |
| Concentration | 1 mg/mL |
| Observed Band | 45kD |
| Subcellular Location | Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Cytoplasm, cytoskeleton, microtubule organizing center, spindle pole body . Cytoplasm . Nucleus . Membrane ; Peripheral membrane protein . Localizes at centrosomes during prometaphase, midzone during anaphase and midbody during telophase/cytokinesis (PubMed:14737111). Membrane localization is probably regulated by its interaction with KSR1 (PubMed:10409742). . |
| Swiss-Prot | Q02750 |
| Gene ID | 5604 |
| Storage | -20°C/1 year |
Reactivity Notes
Validated reactivity: Human, Mouse, Rat. For other species, epitope conservation may allow cross-reactivity; confirm with appropriate controls.
Safety & Handling
This product is for research use only (RUO) and is not intended for diagnostic or therapeutic use. The formulation contains sodium azide; handle with standard laboratory precautions.
Related Products
Explore related antibodies and reagents for MEK-1 (phospho Ser298) research from ELK Biotechnology, or contact us for alternative formats.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
